智通财经APP获悉，美豁免部分产品"对等关税"，港股今日全天强势，三大指数均收涨逾2%，实现五连 涨。截止收盘，恒生指数涨2.4%或502.71点，报21417.4点，全日成交额2533.89亿港元；恒生国企指数 涨2.11%，报7965.81点；恒生科技指数涨2.34%，报5015.12点。 华泰证券指出，往前看，在第一波对等关税扰动发生后，坚定看好港股相对收益表现，原因是：1）产 业上，市场中业绩与关税敏感性较高的出口链及中游制造企业市值占比较低；2）科技企业盈利表现或 将持续支持港股行情演绎；3）外部冲击扰动下，市场或对内需政策存在较大预期。 蓝筹股表现 港交所(00388)表现亮眼。截至收盘，涨6.91%，报334港元，成交额57.31亿港元，贡献恒指43.24点。4 月13日，香港特区政府财政司司长陈茂波发表网志表示，针对全球最新变化，已指示证监会和港交所做 好准备，若在海外上市的中概股希望回流，必须让香港成为它们首选的上市地。港交所亦会加紧做好在 东盟和中东市场的联系和推广工作，吸引更多当地优质企业来港上市，同时汇聚更多国际资金到港，进 一步提升香港国际金融中心的实力和地位。 其他蓝筹股方面，石药 ...

Group 1 - The Hang Seng Index closed up 2.40%, while the Hang Seng Tech Index rose by 2.34% [1] - The gold, retail, and education sectors showed the highest gains [1] - The Hong Kong Stock Tech ETF (159751) increased by 2.23%, and the Hang Seng Hong Kong Stock Connect ETF (159318) rose by 1.28% [1] Group 2 - Chifeng Jilong Gold Mining (600988) surged over 22%, while Dongfang Zhenxuan increased by over 12% [1] - Pop Mart, Xpeng Motors, and WuXi Biologics all saw gains exceeding 6% [1] - Leap Motor declined nearly 6%, and Xiaomi Group fell over 2% [1]

近期受关税政策影响，投资者纷纷寻求较少受到关税影响，可自循环的板块。广发证券今日研报发文指出，当前关税政策对创新药影响远小于其他成长性板 块。创新药License-out的核心盈利模式是"前期授权费+里程碑付款+销售分成"的三段式结构，由于技术授权属于知识产权交易而非实体商品流通，不涉及 HS编码下的关税问题，不直接受贸易政策变化影响。 值得注意的是，今日全市场首只聚集中证港股通医疗主题的ETF（159366）上市交易，首日涨超2%，跟踪的中证港股通医疗主题指数涨超3%，截至发稿， 该ETF仍有2%折价，或存套利空间。 | | 1.063 +0.024 +2.31% | | | | --- | --- | --- | --- | | | SZSE CNY 14:53:12 交易中 | | | | | 净值走势 永赢中证港股通医疗主题ET | | | | 藝比 | -37.28% 委差 | | -31048 | | 卖五 | 1.068 | | 1400 | | 卖四 | 1.067 | | 9342 | | 卖三 | 1.066 | | 19720 | | 美二 | 1.065 | | 15495 | | 英 ...

Investment Rating - The industry investment rating is "Outperform the Market" [52] Core Views - The report emphasizes the ongoing disruptions caused by the US-China tariff policies and suggests focusing on opportunities in non-US markets and import substitution [4][9] - The report highlights that the adjustment of tariffs is expected to impact the trade of pharmaceutical products between China and the US, while companies primarily exporting to markets outside the US will be less affected [4][9] Summary by Sections Tariff Policy Overview - Since April 2, 2025, the US government has imposed a 34% "reciprocal tariff" on Chinese goods, with frequent adjustments to tariff rates and exemptions for certain pharmaceutical products [4][5] - As of April 11, 2025, the tariff rates for bilateral trade between China and the US have been adjusted to 125%, with China indicating it will not respond to further tariff increases from the US [5] Opportunities in the Biopharmaceutical Sector - The report identifies potential for domestic products to increase market share in the blood products sector due to tariff impacts, particularly for albumin, where US imports are significant [9] - It suggests monitoring companies such as Palin Bio, Tiantan Bio, and Huashan Bio for potential growth in market share as import costs rise [9] Medical Devices - The report notes that the tariff policies and anti-dumping investigations are likely to accelerate the domestic substitution process in medical devices, particularly in electrophysiology and imaging fields [10] - Companies like Yirui Technology and United Imaging are highlighted as making progress in domestic production capabilities [10] Investment Strategies - The report recommends focusing on "innovation," "overseas expansion," "equipment upgrades," and "consumption recovery" as key investment themes [12] - Specific companies to watch include BeiGene, Mindray, and Xiamen Innovax for their innovative products and overseas market potential [12] Key Companies to Watch - Notable companies include: - **Nocera Biopharma**: Expected to achieve significant revenue growth with its core product, demonstrating strong cash flow and reduced losses [13][14] - **Sino Biopharmaceutical**: Rapid revenue growth with a focus on innovative products and a strong pipeline [18] - **Kexing Biopharma**: Stable domestic business with promising overseas expansion [18] - **Wuxi Biologics**: Recognized for its strong technical capabilities and expanding overseas operations [22] Market Performance - The report notes a decline in the pharmaceutical sector, with a 5.61% drop in the past week, while the overall market saw a smaller decline [31][42] - The biopharmaceutical sector is highlighted as having the smallest decline among sub-sectors, indicating relative resilience [44]

Group 1 - The Hang Seng Healthcare Index (HSHCI) has seen a strong increase of 2.95%, with notable gains from companies such as Zai Lab (09688) up 12.39% and Dongyangguang Changjiang Pharmaceutical (01558) up 9.04% [3] - The Hang Seng Healthcare ETF (513060) has risen by 3.15%, marking its fourth consecutive increase, with a recent price of 0.46 yuan [3] - Over the past three months, the Hang Seng Healthcare ETF has accumulated a total increase of 21.98% [3] Group 2 - The Hang Seng Healthcare ETF has experienced a net value increase of 26.66% over the past year, with the highest single-month return reaching 28.34% since its inception [4] - The ETF's Sharpe ratio stands at 1.27, indicating strong risk-adjusted returns [4] - The ETF's management fee is 0.50%, and the custody fee is 0.15% [4] Group 3 - The top ten weighted stocks in the Hang Seng Healthcare Index account for 56.37% of the index, with companies like BeiGene (06160) and WuXi Biologics (02269) leading the list [5] - The performance of these stocks varies, with BeiGene showing a gain of 5.34% and WuXi Biologics up by 2.81% [7] Group 4 - The current market environment emphasizes the importance of domestic consumption growth due to pressures from U.S.-China tariffs, highlighting healthcare consumption as a key investment area [8] - The market sentiment is recovering, with a focus on undervalued blue-chip stocks and companies with solid fundamentals, particularly in the healthcare sector [8]

4月11日港股公司回购一览 证券时报·数据宝统计显示，4月11日有45家香港上市公司进行了股份回购，合计回购3765.21万股，回购 金额3.52亿港元。 药明生物回购数量990.00万股，回购金额1.98亿港元，回购最高价为20.250港元，最低价为19.580港元， 年内累计回购金额11.11亿港元；中国宏桥回购数量519.55万股，回购金额6791.51万港元，回购最高价 为13.260港元，最低价为12.840港元，年内累计回购金额13.60亿港元；太古股份公司A回购数量31.50万 股，回购金额1948.77万港元，回购最高价为62.250港元，最低价为61.300港元，年内累计回购金额12.86 亿港元。 以金额进行统计，4月11日回购金额最多的是药明生物，回购金额为1.98亿港元；其次是中国宏桥，回 购金额为6791.51万港元；回购金额居前的还有太古股份公司A、名创优品等。回购数量上看，4月11日 回购股数最多的是协合新能源，当日回购量为1027.00万股；其次是药明生物、中国宏桥等，回购数量 分别为990.00万股、519.55万股。 值得关注的是，本次回购6791.51万港元的中国宏桥，年 ...

1. 友邦保险(01299.HK)拟回购最高达16亿美元的股份。 2. 世茂集团(00813.HK)一季度累计合约销售总额约70.7亿元。 3. 富力地产(02777.HK)3月总销售收入共约11.9亿元，同比增长10.2%。 4. 紫金矿业(02899.HK)一季度归母净利润101.67亿元，同比增长62.39%。 5. 花旗集团增持中国人寿(02628.HK)约514.5万股，每股作价约12.83港元。 6. 中广核新能源(01811.HK)3月完成发电量1765.1吉瓦时，同比减少4.7%。 7. 众安在线(06060.HK)前三个月原保险保费收入约79.57亿元，同比增长12.29%。 8. 君实生物(01877.HK)主席熊俊认可公司长期投资价值，拟增持不低于1亿元的股份。 9. 如祺出行(09680.HK)联手高域科技战略合作，探索"飞行汽车+Robotaxi"智慧交通新场景。 10. 昭衍新药(06127.HK)可能因美国FDA拟取消单克隆抗体及其他药物的动物试验而导致股价异动。 11. 中国太保(02601.HK)：太平洋人寿保险一季度累计原保险保费收入1002.15亿元，同比增长9.3%。 ...

Group 1 - The Shenwan Pharmaceutical Index declined by 5.61% this week, underperforming the CSI 300 Index which fell by 2.87%, ranking 22nd among 31 primary industry indices [1] - As of April 11, 2025, the price-to-earnings (PE) ratio for the pharmaceutical and biotechnology industry is 25.78 times, compared to 11.50 times for the CSI 300 Index, indicating a valuation premium of 124.23% for the pharmaceutical sector, which remains at a historical low [1] Group 2 - The recent changes in U.S. tariff policy, which exempt certain categories of goods from additional tariffs, are seen as a measure to ease U.S.-China trade tensions [2] - The exemption applies to all countries subject to "reciprocal tariffs," allowing products correctly classified under specified HTSUS numbers to benefit from a standard additional tariff of 10% instead of higher rates [2] Group 3 - The easing of tariff pressures is expected to benefit China's electronic and semiconductor supply chains, reflecting the strong competitiveness and cost-effectiveness of Chinese manufacturing [3] - The pharmaceutical industry in China also demonstrates similar supply chain capabilities, indicating a strong global reliance on China's pharmaceutical manufacturing, which reduces the likelihood of imposing high tariffs on drugs [3] Group 4 - The latest tariff policy significantly alleviates export chain pressures, with a focus on investment opportunities in the CXO, API, generic drugs, and medical device sectors [4] - Recommended companies include WuXi AppTec, WuXi Biologics, and others in the CXO chain, as well as Huahai Pharmaceutical and others in the API and generic drug sectors [4]

Group 1: Ningde Times IPO - Ningde Times has received approval from the Hong Kong Stock Exchange for its IPO, aiming to raise at least $5 billion, potentially becoming the largest IPO globally in 2025 [1] - If successful, this IPO will be the largest in Hong Kong since Kuaishou Technology's IPO in 2021, reflecting strong demand in the electric vehicle market [1] Group 2: Tencent and Changan Automobile Collaboration - Tencent and Changan Automobile signed a deepening cooperation agreement in Chongqing to advance smart driving through data sharing and collaboration [2] - This partnership represents an innovative example of data sharing in the automotive industry, enhancing consumer safety and reliability in smart driving experiences [2] Group 3: R&F Properties Sales Growth - R&F Properties reported a total sales revenue of approximately 1.19 billion yuan in March 2025, a year-on-year increase of 10.2%, with a sales area of about 118,400 square meters [3] - Cumulatively, the total sales revenue reached approximately 2.77 billion yuan by the end of March 2025, reflecting a year-on-year increase of 2.21% [3] Group 4: AIA Group Share Buyback - AIA Group announced a share buyback plan with a maximum value of $1.6 billion, demonstrating confidence in its own value [4] - The buyback will be executed by an independent broker on the Hong Kong Stock Exchange, with a duration of up to three months [4] Group 5: WuXi Biologics Share Repurchase - WuXi Biologics announced a repurchase of 9.9 million shares at a total cost of 198 million HKD, with share prices ranging from 19.58 to 20.25 HKD [5] - This repurchase reflects the company's support for its stock price and confidence in its market position [5] Group 6: Hong Kong Stock Market Performance - The Hang Seng Index closed at 20,914.69, with a daily increase of 1.13% on April 11 [6] - The Hang Seng Tech Index rose by 1.80%, closing at 4,900.43, indicating positive market sentiment [6]

Investment Rating - The industry investment rating is "Outperform the Market" [52] Core Viewpoints - The ongoing US-China tariff policies are causing disruptions, suggesting a focus on non-US market expansion and import substitution opportunities in the biopharmaceutical sector [4][9] - The report highlights that the adjustment of tariffs is expected to impact the trade of pharmaceutical products between China and the US, with companies primarily exporting to markets outside the US being less affected [4][9] - The report emphasizes the potential for domestic products to gain market share in the biopharmaceutical sector due to increased tariffs on US imports [9][10] Summary by Sections Tariff Policy Overview - As of April 11, 2025, the tariff rates for bilateral trade between China and the US have been adjusted to 125%, with China indicating it will not respond to further tariff increases from the US [4][5] Biopharmaceutical Sector Insights - The blood products sector is expected to stabilize prices and increase the market share of domestic products due to tariff impacts on imports, particularly for albumin [9] - The medical device sector is anticipated to accelerate domestic substitution due to reliance on North American production, with specific focus on electrophysiology and imaging products [10] - The report suggests monitoring companies such as Palin Bio, Tian Tan Bio, and Huashan Bio for potential growth opportunities in the blood products market [9][10] Investment Strategies - The report recommends focusing on "innovation," "overseas expansion," "equipment upgrades," and "consumer recovery" as key investment themes [12] - Specific companies highlighted for innovation include BeiGene, Dongcheng Pharmaceutical, and others with strong global competitiveness [12] - Companies like Mindray Medical and United Imaging are noted for their potential in overseas markets [12] Key Companies to Watch - Notable companies include: - **Nocera Biopharma**: Expected to achieve significant revenue growth with its core product, showing a 49% year-on-year increase in sales [13] - **Sino Biopharmaceutical**: Rapid revenue growth with a focus on innovative products [18] - **Kexing Biopharma**: Stable domestic business with promising overseas expansion [18] - The report also highlights the potential of companies like East China Pharmaceutical and others in the nuclear medicine sector [17] Market Performance - The biopharmaceutical sector has seen a decline of 5.61% recently, with specific sub-sectors experiencing varying levels of impact [31][44]